HomeScience & DiscoveryResearch & DevelopmentClinical DevelopmentPublicationsProductsTeamNews and EventsCareersContact Us

HemoMex™ Injection 2000 mg/100 ml approved as a prescription drug by Public Health Ministry of the Republic of Uzbekistan
Tashkent, Republic of Uzbekistan, and Pegasus Pharmaceuticals Group Inc., BC, Canada, June 8, 2010 --- Pegasus Pharmaceuticals Group Inc. announced that Pharmacopoeia Committee, Public Health Ministry of the Republic of Uzbekistan has issued a new drug approval for HemoMex™ Dammarane Sapogenins (Ginseng Sapogenins) Injection 2000 mg/100 ml on May 7, 2010. A Selective Metabolites Compound Drug (SMCD)-based innovative HemoMex™ Dammarane Sapogenins Injection was approved as a prescription drug which can be used in combination with chemotherapeutic agents and/or radiotherapy for solid tumors, and used for the treatment of neutropenia complicated to chemotherapy and/or radiotherapy.

HemoMex S™ Capsule 150mg Approved as Drug by the Ministry of Health, Republic of Georgia
Pegasus Pharmaceuticals Group Inc. announced that the Agency of State Regulation of Medical Activity of the Ministry of Labour, Health and Social Affairs of Georgia has issued a new drug approval for HemoMex S™ Capsule of Dammarane Sapogenins 150 mg on March 22, 2010.

HemoMex S™ Softgel Capsule of Dammarane Sapogenins 80 mg Approved as Drug by the Ministry of Health, Republic of Georgia
Pegasus Pharmaceuticals Group Inc. announced that the Agency of State Regulation of Medical Activity of the Ministry of Labour, Health and Social Affairs of Georgia has issued a new drug approval for  HemoMex S™ Softgel Capsule of Dammarane Sapogenins 80 mg on September 28, 2009. An OBET-based self-microemulsifying drug delivery system (SMEDDS) HemoMex S™ Softgel Capsule of Dammarane Sapogenins 80 mg was approved as a prescription drug (drug license number: No.R-001177) which can be used in combination with chemotherapeutic agents and/or radiotherapy for solid tumors.

Sino-Canadian Symposium on Advanced Biomedical Technologies
On May 6th, 2009, at the Canadian Embassy in Beijing, China, Pegasus Pharmaceuticals Group Inc. jointly organized the “Sino-Canadian Symposium on Advanced Biomedical Technologies” with the Canadian Embassy in China and SinoBioway Group Co. Ltd. of Peking University, China.  Over 50 high ranking guests participated in this symposium, including senior government officials, scientists from renowned universities and research institutes who are experts in the biomedical and botanical drug research.

Four Botanical Small-molecule Products Approved as Drugs by the Ministry of Health, Republic of Georgia
HemoMex I, CanaQ capsules, Lipo-Aid and Cardio Guard.

Pegasus Attended the 5th Chinese Conference on Oncology (CCO)
The fifth Chinese Conference on Oncology took place in Shijiazhuang city, Hebei province, China from Sept. 19-22, 2008.  This conference was organized by the Chinese Anti-cancer Association, Oncology Division of the Chinese Medical Association, and co-hosted by International Union Against Cancer (UICC), Health Bureau of Hebei Province and Hebei Medical University, China.

Pegasus attended the 5th Conference of Oncologists & Radiologists of CIS countries
In May 2008, the Conference of Oncologists and Radiologists of CIS countries (former states of Soviet Union) took place in Tashkent, capital of Uzbekistan in Central Asia. About 1400 scholars and medical doctors from CIS countries as well as other countries such as Germany, India, Canada, Poland, Serbia, Czech Republic and Sweden attended this event.

Pegasus Attended the 3rd Israel-Georgia International Medical Conference
From June 26 - July 3, 2008, the third Israel - Georgia International Medical Conference was held in Tel Aviv, Israel. The conference theme was “Reality and Prospects of Medical Sciences --- from Theoretical Scientific Research to Clinical Application”.  Scientists and scholars from various leading medical centers and research institutions of Israel and Republic of Georgia and specializing in the research of cancer, cardiovascular and metabolic disease attended this conference.

Product licences granted by Health Canada

2010.07.05
Careseng NutroPro FIT capsule (400 mg/capsule) granted product license by Health Canada. Product Number (NPN): 80020587.

2010.06.07
Careseng DH-plus softgel capsule (80 mg/capsule) granted product license by Health Canada. Product Number (NPN): 80018899.

2010.05.25
Careseng DH softgel capsule (50 mg/capsule) granted product license by Health Canada. Product Number (NPN): 80018952.

 
Copyright © 2002-2010 Panagin Pharmaceuticals Inc. All rights reserved.
中文 English